Literature DB >> 30442728

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.

Simon Rule1, Martin Dreyling2, Andre Goy3, Georg Hess4, Rebecca Auer5, Brad Kahl6, José-Ángel Hernández-Rivas7, Keqin Qi8, Sanjay Deshpande8, Lori Parisi8, Michael Wang9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30442728      PMCID： PMC6518912          DOI： 10.3324/haematol.2018.205229

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.

Authors:  Myron S Czuczman; A Goy; D Lamonica; D A Graf; M C Munteanu; R H van der Jagt
Journal:  Ann Hematol       Date:  2015-09-28       Impact factor: 3.673

2.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Authors:  Christian W Eskelund; Christina Dahl; Jakob W Hansen; Maj Westman; Arne Kolstad; Lone B Pedersen; Carmen P Montano-Almendras; Simon Husby; Catja Freiburghaus; Sara Ek; Anja Pedersen; Carsten Niemann; Riikka Räty; Peter Brown; Christian H Geisler; Mette K Andersen; Per Guldberg; Mats Jerkeman; Kirsten Grønbæk
Journal:  Blood       Date:  2017-08-17       Impact factor: 22.113

3.  Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

Authors:  Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; Nora Cavazos; Black Liu; Shiyi Yang; Fong Clow; Jenna D Goldberg; Darrin Beaupre; Jessica Vermeulen; Mark Wildgust; Michael Wang
Journal:  Br J Haematol       Date:  2017-08-18       Impact factor: 6.998

4.  Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Authors:  Constantine S Tam; Mary Ann Anderson; Christiane Pott; Rishu Agarwal; Sasanka Handunnetti; Rodney J Hicks; Kate Burbury; Gillian Turner; Juliana Di Iulio; Mathias Bressel; David Westerman; Stephen Lade; Martin Dreyling; Sarah-Jane Dawson; Mark A Dawson; John F Seymour; Andrew W Roberts
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.

Authors:  Binay Kumar Shah; Amit Khanal
Journal:  Anticancer Res       Date:  2015-06       Impact factor: 2.480

7.  Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Authors:  Peter Dreger; Mauricette Michallet; Paul Bosman; Sascha Dietrich; Mohamad Sobh; Ariane Boumendil; Arnon Nagler; Christof Scheid; Jan Cornelissen; Dietger Niederwieser; Lutz Müller; Elizabeth Vandenberghe; Ilaria Scortechini; Helene Schoemans; Niels S Andersen; Jürgen Finke; Domenico Russo; Per Ljungman; Jakob Passweg; Michel van Gelder; Nadira Durakovic; Helene Labussiere-Wallet; Tobias Berg; Gerald Wulf; Wolfgang Bethge; Donald Bunjes; Stefan Stilgenbauer; Maria Elisa Canepari; Michel Schaap; Christopher P Fox; Nicolaus Kröger; Silvia Montoto; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2018-05-04       Impact factor: 5.483

8.  Improvement of overall survival in advanced stage mantle cell lymphoma.

Authors:  Annina Herrmann; Eva Hoster; Thomas Zwingers; Günter Brittinger; Marianne Engelhard; Peter Meusers; Marcel Reiser; Roswitha Forstpointner; Bernd Metzner; Norma Peter; Bernhard Wörmann; Lorenz Trümper; Michael Pfreundschuh; Hermann Einsele; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Authors:  Martin Dreyling; Wojciech Jurczak; Mats Jerkeman; Rodrigo Santucci Silva; Chiara Rusconi; Marek Trneny; Fritz Offner; Dolores Caballero; Cristina Joao; Mathias Witzens-Harig; Georg Hess; Isabelle Bence-Bruckler; Seok-Goo Cho; John Bothos; Jenna D Goldberg; Christopher Enny; Shana Traina; Sriram Balasubramanian; Nibedita Bandyopadhyay; Steven Sun; Jessica Vermeulen; Aleksandra Rizo; Simon Rule
Journal:  Lancet       Date:  2015-12-07       Impact factor: 79.321

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  31 in total

1.  Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.

Authors:  Alberto Fabbri; Emanuele Cencini; Angela Giovanna Congiu; Maurizio Miglino; Luigi Rigacci; Monica Bocchia
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.

Authors:  Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull
Journal:  Blood Adv       Date:  2021-03-23

3.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Authors:  Peter Martin; Nancy L Bartlett; Kristie A Blum; Steven Park; Kami Maddocks; Jia Ruan; LeAnn Ridling; Christopher Dittus; Zhengming Chen; Xiangao Huang; Giorgio Inghirami; Maurizio DiLiberto; Selina Chen-Kiang; John P Leonard
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

Review 4.  Management of Older Adults with Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

5.  Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.

Authors:  Zhiyuan Zhou; Lei Zhang; Xinhua Wang; Xin Li; Ling Li; Xiaorui Fu; Xudong Zhang; Zhaoming Li; Zhenchang Sun; Mingzhi Zhang
Journal:  Ann Hematol       Date:  2021-04-26       Impact factor: 3.673

Review 6.  Sequencing of Novel Therapies for Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Curr Treat Options Oncol       Date:  2021-11-23

Review 7.  Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.

Authors:  Meri Tarockoff; Teresita Gonzalez; Stanislav Ivanov; Jose Sandoval-Sus
Journal:  Curr Oncol Rep       Date:  2022-05-31       Impact factor: 5.945

8.  HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.

Authors:  Ziwen Lu; Zhixin Wang; Zhigang Tu; Hanqing Liu
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

9.  CircCTNNA1 is Upregulated in Mantle Cell Lymphoma and Predicts Poor Survival by Sponging miR-34a to Increase Cell Proliferation.

Authors:  Cong Lu; Chao Song; Qingkun Han; Xuebing Jing
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

10.  Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Authors:  Preetesh Jain; Shaojun Zhang; Rashmi Kanagal-Shamanna; Chi Young Ok; Krystle Nomie; Graciela Nogueras Gonzalez; Omarya Gonzalez-Pagan; Holly A Hill; Hun Ju Lee; Luis Fayad; Jason Westin; Loretta Nastoupil; Frederick Hagemeister; Wendy Chen; Onyeka Oriabure; Maria Badillo; Changying Jiang; Yao Yixin; Shaoying Li; Guilin Tang; C Cameron Yin; Keyur P Patel; Leonard Jeffrey Medeiros; Ranjit Nair; Sairah Ahmed; Swaminathan P Iyer; Selvi Thirumurthi; Richard Champlin; Guofan Xu; Pan Tinsu; David Santos; Ruiping Wang; Guangchun Han; Jianhua Zhang; Xingzhi Song; Sattva Neelapu; Jorge Romaguera; Andy Futreal; Christopher Flowers; Nathan Fowler; Linghua Wang; Michael L Wang
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.